No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Based in Marburg, Germany, NanoRepro AG specializes in the development, manufacturing, and international distribution of both swift diagnostic tests and nutritional supplements, serving individual consumers and healthcare professionals alike. Their diagnostic offerings encompass family planning, various disease detection, identification of food intolerances, allergies, and infectious diseases. This portfolio includes dedicated rapid test lines for allergies, family planning, and preventive healthcare. For hospitals and medical practices, they provide point-of-care tests capable of detecting conditions such as HIV, human cardiac Troponin I, D-dimer, streptococci antigens, influenza types A and B, and microalbumin. The company also produces immunochromatographic lateral flow tests for biomarker identification, alongside rapid SARS-CoV-2 antibody and antigen tests. Complementing their diagnostics, NanoRepro AG offers food supplements tailored for men and women, distributed via online stores and pharmacies.
www.nanorepro.comNo one on the platform currently holds NN6.DE.
No tracked institution reports a position in NN6.DE as of their last filing.
No one on the platform has traded NN6.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 0.1% | -22.8% | ||||
| Profit Margin % | -42.7% | -45.1% | -39.0% | |||
| Free Cash Flow Margin % | 0.0% | -17.7% | -25.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $18M | +17.8% | $-0.13 | $-0.13–$-0.13 | — | 1 |
| 2027 | $23M | +24.9% | $-0.03 | $-0.03–$-0.03 | — | 1 |
| 2028 | $25M | +9.3% | $0.12 | $0.12–$0.12 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| NN6.DENanoRepro AG | $1.70 | -1.17% | $21M | — |
| AAQ1.DEaap Implantate AG | $1.68 | +1.20% | $25M | — |
| BNN.DEBRAIN Biotech AG | $2.72 | -2.16% | $59M | — |
| E8X.DEelexxion AG | $0.14 | +1.45% | $1M | — |
| GME.DEGeratherm Medical AG | $2.45 | +0.00% | $13M | — |
| M3V.DEMeVis Medical Solutions AG | $23.80 | +0.00% | $43M | — |
| MAK.DEMaternus-Kliniken AG | $0.86 | +0.00% | $18M | — |
Source: Financial Modeling Prep · peers by sector/industry